TGA warns against importing unapproved peptides sold online for anti-ageing

What happened

In April and May 2026, the Therapeutic Goods Administration issued back-to-back safety alerts about a sharp rise in unapproved injectable peptides circulating across Australia. The TGA warning published in May specifically names products containing BPC-157, TB-500 (thymosin beta-4), GHK-Cu, retatrutide, and CJC-1295.

These products are being marketed across social media and online platforms with health claims: anti-ageing, wound healing, muscle repair, fat loss, cognitive enhancement, and enhanced athletic performance. Most arrive as injectable vials labelled “research use only” or “not for human consumption.” Under Australian law, that labelling does not change their status as therapeutic goods — and none are approved, registered, or listed on the Australian Register of Therapeutic Goods for human use.

This is not a fringe phenomenon. Researchers from the University of Queensland and UNSW, writing in The Conversation in April 2026, documented that injectable peptides have moved from bodybuilding subcultures into wellness communities, private clinics, and mainstream consumer awareness. The TGA’s alerts follow a separate advisory to healthcare practitioners about responsibilities when importing, compounding, and supplying these products — an acknowledgement that the products are also finding their way into clinic settings.

What these peptides are — and what the evidence actually shows

Peptides are short chains of amino acids. The body uses them as signalling compounds, and some TGA-approved medications are peptides — insulin, semaglutide, and various hormones among them. The appeal of synthetic peptides as therapeutics is real: they tend to be more targetable than small-molecule drugs, and the category has genuine medical applications.

The question is whether the specific peptides circulating in the online wellness market have the evidence to justify human use. The honest answer is no.

BPC-157 (body-protection compound 157) is the most heavily marketed. It has been studied in animal models for wound healing, gut protection, and tendon repair, with some positive signals in rodent studies. The UQ/UNSW researchers identified only three small human studies — none were randomised controlled trials, and none included a control group. Human safety data is essentially absent. BPC-157 is listed as a Schedule 4 poison in Australia — meaning it requires a prescription — yet is widely sold online without any prescribing framework.

TB-500 (synthetic thymosin beta-4) is marketed for muscle repair and recovery. Thymosin beta-4 has known roles in tissue-repair pathways in animal models. Evidence in humans is not established. GHK-Cu (copper peptide) appears in anti-ageing skin products and injectable formulations. CJC-1295 is a growth-hormone-releasing hormone analogue. Retatrutide is an investigational GIP/GLP-1/glucagon tri-agonist still in clinical trials and not approved for commercial use anywhere.

The contrast with approved GLP-1 medications is instructive. Semaglutide (Ozempic, Wegovy) is a peptide. It went through extensive phase-3 clinical trials involving tens of thousands of participants, received TGA approval for specific indications with defined eligibility criteria, has a well-characterised side-effect profile, requires monitoring, and is prescribed within a clinical framework. The peptides arriving in online vials have none of that scaffolding.

The specific risks the TGA is flagging

The risk is not merely theoretical lack of efficacy. It is safety genuinely unknown — and unknown in ways that matter for a product being injected.

Products referred to the TGA by Australian Border Force are frequently poorly labelled, with no way to verify contents, concentration, or sterility. Injectable products not manufactured to pharmaceutical-grade sterility standards carry infection risk: localised abscess at best, systemic sepsis at worst. Contamination with undeclared substances is a real possibility.

There is also an interaction risk that receives no attention in social media marketing: peptides that modulate immune signalling, growth-factor pathways, or metabolic hormones may interact with existing conditions or medications. A person managing an autoimmune condition with a biologic agent, or taking thyroid replacement, who adds an unregulated peptide that touches similar pathways is operating in territory where no-one has mapped the risks.

The TGA’s concern extends beyond individual consumers. newsGP has noted that some clinics have been caught up in the peptide supply chain — either prescribing, compounding, or supplying products outside the approved regulatory framework. The TGA’s simultaneous advisory to practitioners makes clear that healthcare professionals are also on notice.

The felt reality behind the trend

The audience for these products is not fringe. It is health-conscious, self-researching people — often women in their 40s and beyond — who have felt dismissed by a medical system that runs a blood panel, returns normal results, and ends the conversation. When conventional medicine says “your bloods are fine” and offers nothing further for fatigue, body-composition changes, or recovery concerns, it is unsurprising that people look for products that seem to offer specificity and effect.

That frustration is real and worth taking seriously. The answer to it, however, is not unregulated injectables with no human safety data.

If the underlying concern is body composition after 40, or metabolic health, or musculoskeletal recovery, or low energy that is not explained by routine testing: there are approaches the evidence does support. A GP with interest in lifestyle and metabolic health can work through what those approaches look like in a structured way. These conversations take time and the system does not always make them easy to have — but they are worth pursuing before purchasing a product that nobody has safety-tested in a human.

Verdict

Verdict: yes — worth knowing about.

If you have seen injectable peptides promoted in wellness communities or on social media, this TGA warning is the regulatory signal to pause. The human safety data is not there. The regulatory framework that would tell you what is actually in the vial is not there. Approved options exist — supported by clinical trial data — for the underlying concerns these products claim to address, and those options are worth exploring through your GP.

---

Sources cited

1. TGA — Warning on the risks of importing unapproved peptide products (May 2026)
2. TGA — Understanding responsibilities when importing, compounding and supplying unapproved peptide products
3. UQ/UNSW — Injectable peptides are the new anti-ageing trend. But what evidence do we have they’re safe for humans? The Conversation, April 2026
4. newsGP — TGA issues warning against unapproved peptides